{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Drug+A+%28Blinded+Drug%29&page=8",
    "query": {
      "intervention": "Drug A (Blinded Drug)",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 972,
    "total_pages": 98,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Drug+A+%28Blinded+Drug%29&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Drug+A+%28Blinded+Drug%29&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T13:26:27.445Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06630286",
      "title": "Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1-infection"
      ],
      "interventions": [
        {
          "name": "ISL/LEN",
          "type": "DRUG"
        },
        {
          "name": "B/F/TAF",
          "type": "DRUG"
        },
        {
          "name": "PTM B/F/TAF",
          "type": "DRUG"
        },
        {
          "name": "PTM ISL/LEN",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 609,
      "start_date": "2024-10-09",
      "completion_date": "2030-08",
      "has_results": false,
      "last_update_posted_date": "2026-04-30",
      "last_synced_at": "2026-10-14T13:26:27.445Z",
      "location_count": 60,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 50 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06630286"
    },
    {
      "nct_id": "NCT00051779",
      "title": "An Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) in Patients With Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Neoplasms",
        "Breast Cancer",
        "Metastasis"
      ],
      "interventions": [
        {
          "name": "CAL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Chugai Pharma USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-10-14T13:26:27.445Z",
      "location_count": 38,
      "location_summary": "Little Rock, Arkansas • Springdale, Arkansas • Concord, California + 32 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00051779"
    },
    {
      "nct_id": "NCT07465653",
      "title": "A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Heart Failure With Reduced Ejection Fraction"
      ],
      "interventions": [
        {
          "name": "HJB647 low dose",
          "type": "DRUG"
        },
        {
          "name": "HJB647 high dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 12,
      "start_date": "2026-03-18",
      "completion_date": "2026-12-08",
      "has_results": false,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-14T13:26:27.445Z",
      "location_count": 5,
      "location_summary": "Bradenton, Florida • Inverness, Florida • Jacksonville, Florida + 2 more",
      "locations": [
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Inverness",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07465653"
    },
    {
      "nct_id": "NCT02793375",
      "title": "Does Montelukast Decrease Post Adenotonsillectomy Pain in Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pain"
      ],
      "interventions": [
        {
          "name": "Montelukast",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital Medical Center, Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "8 Years",
        "sex": "ALL",
        "summary": "3 Years to 8 Years"
      },
      "enrollment_count": 116,
      "start_date": "2018-08-02",
      "completion_date": "2024-11-19",
      "has_results": true,
      "last_update_posted_date": "2026-04-21",
      "last_synced_at": "2026-10-14T13:26:27.445Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02793375"
    },
    {
      "nct_id": "NCT03642028",
      "title": "Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Sleep Initiation and Maintenance Disorders",
        "Stress Disorders, Posttraumatic"
      ],
      "interventions": [
        {
          "name": "Suvorexant",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 190,
      "start_date": "2019-08-30",
      "completion_date": "2025-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-07-18",
      "last_synced_at": "2026-10-14T13:26:27.445Z",
      "location_count": 4,
      "location_summary": "Long Beach, California • San Francisco, California • Salisbury, North Carolina + 1 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Salisbury",
          "state": "North Carolina"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03642028"
    },
    {
      "nct_id": "NCT03580707",
      "title": "Does BRV Have Faster Onset Time & Greater Effect Than LEV in Epilepsy Pts Using PPR Pharmacodynamic Efficacy Endpoint",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Photosensitive Epilepsy"
      ],
      "interventions": [
        {
          "name": "BRV vs LEV in randomized double blinded, crossover fashion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rosenfeld, William E., M.D.",
      "sponsor_class": "INDIV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 16,
      "start_date": "2018-06-01",
      "completion_date": "2018-12-31",
      "has_results": false,
      "last_update_posted_date": "2019-03-26",
      "last_synced_at": "2026-10-14T13:26:27.445Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03580707"
    },
    {
      "nct_id": "NCT03098420",
      "title": "Dose Escalation of Dexamethasone to Increase Duration of Transversus Abdominal Plane Block Following Cesarean Section",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Post Surgical Pain"
      ],
      "interventions": [
        {
          "name": "2mg Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "4mg Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Ropivacaine (TAP blocks)",
          "type": "DRUG"
        },
        {
          "name": "Morphine",
          "type": "DRUG"
        },
        {
          "name": "Bupivacaine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Normal saline 1ml",
          "type": "DRUG"
        },
        {
          "name": "Normal saline 0.5ml",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 29,
      "start_date": "2016-07",
      "completion_date": "2021-05-20",
      "has_results": true,
      "last_update_posted_date": "2021-06-18",
      "last_synced_at": "2026-10-14T13:26:27.445Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03098420"
    },
    {
      "nct_id": "NCT03741920",
      "title": "Evaluation of the Personal KinetiGraph™ (PKG™) to Improve Insight Into Parkinson's Disease Status",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "Personal KinetiGraph™ (PKG™)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Global Kinetics Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "46 Years",
        "maximum_age": "83 Years",
        "sex": "ALL",
        "summary": "46 Years to 83 Years"
      },
      "enrollment_count": 231,
      "start_date": "2017-05-17",
      "completion_date": "2025-10",
      "has_results": false,
      "last_update_posted_date": "2025-09-04",
      "last_synced_at": "2026-10-14T13:26:27.445Z",
      "location_count": 12,
      "location_summary": "Sacramento, California • San Diego, California • Boca Raton, Florida + 9 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03741920"
    },
    {
      "nct_id": "NCT02688270",
      "title": "Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Raynaud's Phenomenon Secondary to Connective Tissue Disease"
      ],
      "interventions": [
        {
          "name": "Vascana (0.9% nitroglycerin cream)",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Cream (placebo)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Covis Pharma S.à.r.l.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 65,
      "start_date": "2016-06",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2022-11-02",
      "last_synced_at": "2026-10-14T13:26:27.445Z",
      "location_count": 1,
      "location_summary": "Multiple Locations, Pennsylvania",
      "locations": [
        {
          "city": "Multiple Locations",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02688270"
    },
    {
      "nct_id": "NCT01192880",
      "title": "A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Bitopertin",
          "type": "DRUG"
        },
        {
          "name": "Antipsychotics",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 625,
      "start_date": "2010-11",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2017-02-15",
      "last_synced_at": "2026-10-14T13:26:27.445Z",
      "location_count": 27,
      "location_summary": "Costa Mesa, California • Escondido, California • Granada Hills, California + 24 more",
      "locations": [
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Granada Hills",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01192880"
    }
  ]
}